Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 71

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 71
---
.

  49  

On
August 27, 2024, the Company announced that the Phase 3 DETECT-trial evaluating macimorelin for the diagnosis of Childhood Onset Growth
Hormone Deficiency (CGHD) had failed to meet its primary endpoints according to the definitions in the study protocol. Based on the results
of the study, we are prioritizing our pipeline moving forward and repositioning the Company as a pure play Life Science’s business
offering natural-based products. Therefore, while macimorelin for the diagnosis of Adult Growth Hormone Deficiency is still on the market,
the Company has decided to not make any future investments in macimorelin for the diagnosis of CGHD and is exploring and validatingseveral options for its commercialization with adults.

Macimorelin
Commercialization Program

Macrilen ® ®

Avenanthramides
for Potential Applications in Inflammation Based Diseases

Avenanthramides
have garnered significant interest due to their suggested bioactivities, including potent antioxidant and anti-inflammatory effects both in vitro in vivo

Subjects
received doses ranging from 30mg to 960mg per group per day. Given that no significant adverse reactions have been observed during SAD
and MAD phases, The Data Safety and Monitoring Board gave the green light to start the Phase 2a with patients suffering from mild inflammation.
A total of 24 patients will be enrolled in the Phase 2a portion which is designed to gather initial insights into its potential efficacy.
As the trial progresses, the Company remains focused on collaborating with regulatory authorities, healthcare professionals, and patient
communities to bring this innovative therapy to market.

  50  

Consolidated
Statements of Loss and Comprehensive Loss Data

  (in thousands of US dollars, except loss per share)                      Three months ended                                    Twelve months ended                                               
                                                                           December 31,                                          December 31,                                                      
                                                                           2024                                                  2024                                                              
                                                                                                           $              $                                       $              $                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenues                                                                                             3,322          1,213                                   9,587          7,143         14,572  
  Cost of sales                                                                                       (1,273         (1,066                                  (4,858         (4,205         (6,016  
  Gross profit                                                                                         2,049            147